Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | President, Worldwide R&D | September 13, 2024 | September 17, 2024 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 20, 2023 | January 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 13, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,074 |
Ending reported balance
After 2024-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 197,172 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-09-13 · Tax withholding · Disposed 12,098 · Balance 185,074 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
Mirati Therapeutics, Inc.
Report date January 20, 2023 · Filed January 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,465 |
Reported balance
After 2023-01-20 transaction · row 1
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 4,444 · Balance 10,465 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 7,520 |
Reported balance
After 2023-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-20 · Grant · Acquired 7,520 · Balance 7,520 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 6,878 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.01 · Expires 2026-06-12 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2024 Filed Sep 17, 2024 21:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 12,098 | $84.90 | $1,027,120.20 |
DisclosureSEC source: 0001048477-24-000141 · wk-form4_1726610040.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,074 Read SEC document |
| April 30, 2024 Filed Sep 17, 2024 21:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 300 | $68.65 | $20,593.80 |
DisclosureSEC source: 0001048477-24-000141 · wk-form4_1726610040.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,172 F1 · date: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to Buy Common Stock) · Derivative | 40,860 | $0.00 Strike: $83.87 | $0.00 |
DisclosureSEC source: 0001048477-24-000042 · wk-form4_1710895563.xml · derivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,860 Underlying: Common Stock · 40,860 shares Expires 2034-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 33,485 | $83.87 | $2,808,386.95 |
DisclosureSEC source: 0001048477-24-000042 · wk-form4_1710895563.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,872 Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 18,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000042 · wk-form4_1710895563.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,357 F1 · price: Restricted stock units granted March 15, 2024. Price not applicable. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 23:54 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 35,341 | $85.18 | $3,010,395.86 |
DisclosureSEC source: 0001048477-24-000034 · wk-form4_1709855648.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,117 F1 · price: The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.01 to $85.31. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 9,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000020 · wk-form4_1709244617.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,458 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 13,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000020 · wk-form4_1709244617.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,220 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:10 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 30,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000020 · wk-form4_1709244617.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,894 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 17,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000049 · wk-form4_1701813402.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,254 F2 · price: Restricted stock units granted on December 1, 2023. Price not applicable. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 17:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 12,000 | $90.43 | $1,085,110.80 |
DisclosureSEC source: 0001048477-23-000037 · wk-form4_1691776761.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,187 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $90.40 to $90.515. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 28, 2023 Filed Dec 5, 2023 21:56 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 317 | $66.88 | $21,200.33 |
DisclosureSEC source: 0001048477-23-000049 · wk-form4_1701813402.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,504 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2023 Filed Mar 18, 2023 01:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 36,000 | $93.41 | $3,362,760.00 |
DisclosureSEC source: 0001567619-23-005295 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,187 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 38,450 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005295 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,450 Underlying: Common Stock · 38,450 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2024 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 4,799 | $87.74 | $421,064.26 |
DisclosureSEC source: 0001567619-23-005295 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,187 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 16,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005295 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,986 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 13,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014606 · doc4.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,146 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 18,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014606 · doc4.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,754 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 36,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014606 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,534 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001040 · marketforms-58265.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001040 · marketforms-58265.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,465 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| April 29, 2022 Filed Feb 11, 2023 02:46 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 341 | $62.41 | $21,280.79 |
DisclosureSEC source: 0001567619-23-002420 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,094 F1 · date: Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,259 | $80.72 | $182,346.48 |
DisclosureSEC source: 0001567619-22-007187 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,753 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 35,830 | $0.00 Strike: $78.27 | $0.00 |
DisclosureSEC source: 0001567619-22-007187 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,830 Underlying: Common Stock · 35,830 shares Expires 2032-03-14 F2 · derivative.exercise_date: Option grant vests 12/48th on March 15, 2023 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 12,101 | $78.27 | $947,145.27 |
DisclosureSEC source: 0001567619-22-007187 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,012 Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 01:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 38,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007187 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,113 F1 · price: Restricted stock units granted on March 15, 2022. Price not applicable. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:38 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 12,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006718 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,323 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return for 2019 through 2021 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 100% vests on March 15, 2022, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $20.54 | $0.00 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · derivative · entry 7 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $20.54 | $0.00 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · derivative · entry 6 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2024-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 210 | $106.34 | $22,331.55 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · nonDerivative · entry 5 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $106.33 to $106.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 8,700 | $105.80 | $920,427.81 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,231 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $105.28 to $106.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 2,090 | $104.76 | $218,958.01 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $104.23 to $105.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 5,000 | $20.54 | $102,700.00 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. Read SEC document |
| February 11, 2022 Filed Feb 14, 2022 16:51 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 6,000 | $20.54 | $123,240.00 |
DisclosureSEC source: 0001214659-22-002681 · marketforms-55390.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000847 · marketforms-55081.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:21 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000847 · marketforms-55081.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,021 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| April 30, 2021 Filed Feb 12, 2022 02:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 341 | $62.41 | $21,280.79 |
DisclosureSEC source: 0001567619-22-003783 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,483 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 01:12 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,454 | $78.52 | $192,688.08 |
DisclosureSEC source: 0001567619-21-006820 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,142 Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 2,259 | $77.21 | $174,417.39 |
DisclosureSEC source: 0001567619-21-006551 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,596 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 37,710 | $0.00 Strike: $78.39 | $0.00 |
DisclosureSEC source: 0001567619-21-006551 · doc1.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,710 Underlying: Common Stock · 37,710 shares Expires 2031-03-14 F2 · date: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 7,460 | $78.39 | $584,789.40 |
DisclosureSEC source: 0001567619-21-006551 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,855 Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 01:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 15,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006551 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,315 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:16 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 2,155 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000679 · marketforms-50978.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:16 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000679 · marketforms-50978.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.54 | $0.00 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · derivative · entry 9 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 40 | $237.90 | $9,516.00 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 8 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 451 | $237.36 | $107,048.86 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 7 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $236.90 to $237.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,821 | $235.19 | $428,283.90 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 6 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,491 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $234.99 to $235.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 610 | $234.27 | $142,906.90 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 5 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,312 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $233.93 to $234.514. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 4,461 | $233.40 | $1,041,207.21 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,922 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $232.84 to $233.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.